We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Orexo AB (ORX) NPV

Sell:19.60 SEK Buy:19.70 SEK Change: 1.48 SEK (8.10%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Sell:19.60 SEK
Buy:19.70 SEK
Change: 1.48 SEK (8.10%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Sell:19.60 SEK
Buy:19.70 SEK
Change: 1.48 SEK (8.10%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Contact details

Rapsgatan 7E
751 05
+46 (18) 7808800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
634.51 million SEK
Shares in issue:
35.11 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Nikolaj Sorensen
    President, Chief Executive Officer
  • Joseph DeFeo
    Chief Financial Officer, Executive Vice President
  • Robert Deluca
    President of Orexo US Inc.
  • Dennis Urbaniak
    Executive Vice President - Digital Therapeutics
  • Cecilia Coupland
    Senior Vice President and Head of Operations
  • Robert Roenn
    Senior Vice President and Head of Research and Development
  • Michael Sumner
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.